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We developed an AIDS vaccine for Western and West-Central Africa based on a DNA plasmid vector expressing HIV-1 recombinant
subtype CRF02_AG gag, pol, and env genes. To optimize the production of noninfectious HIV-like particles (VLPs) and potentially improve
the effectiveness of the vaccine, we generated four potential vaccine constructs: the parental (IC2) and three modifications (IC25, IC48, and
IC90) containing mutations within the HIV protease. While the parental construct IC2 expressed aggregates of Gag proteins, the IC25
construct resulted in the production of immature VLPs (the core comprises unprocessed Pr55Gag). The remaining two constructs (IC48 and
IC90) produced mature VLPs (the core comprises processed capsid p24) in addition to immature VLPs and aggregates of Gag proteins. VLPs
incorporated significant levels of mature gp120 envelope glycoprotein. Importantly, the mature VLPs were fusion competent and entered
coreceptor-specific target cells. The production of multiple antigenic forms, including fusion-competent VLPs, by candidate DNA vaccine
constructs may provide immunologic advantages for induction of protective cellular and humoral responses against HIV-1 proteins.
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The quest to identify an effective human immunodefi-
ciency virus (HIV) vaccine has resulted in the development
of many novel candidates. Because of the lack of knowl-
edge of correlates of immune protection, many vaccine
approaches and concepts are being pursued. Vaccines have
been designed to raise cellular immunity to control virulent
challenges and shown to prevent the development of AIDS0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2003.10.013
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2000, 2001; Rose et al., 2001; Shiver et al., 2002).
Vaccination with plasmid DNA alone can elicit both
humoral and cellular immune responses (Tang et al.,
1992; Ulmer et al., 1993; Wolff et al., 1990) that protect
nonhuman primates against challenges with nonpathogenic
AIDS viruses (Boyer et al., 1997; Letvin et al., 1997) and
afford modest protection against disease from pathogenic
simian immunodeficiency virus (SIV) (Egan et al., 2000;
Lu et al., 1996). Another approach to raise cellular
immunity is the use of DNA to prime an immune response
followed by recombinant poxvirus boosters such as the
modified vaccinia virus Ankara (Amara et al., 2001;
Robinson et al., 2000). Including multiple HIV-1 gene
regions on the same construct augments this approach, as
both gag and env responses are important to protection
against virus challenge (Amara et al., 2002).
One further theoretical advantage of multigene HIV-1
DNA vaccines is an opportunity to generate noninfectious
HIV-like particles (VLPs). Ideally, VLPs are generated by
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well-defined epitopes in a native conformation, obviating
the problem of HLA restriction and effective stimulation of
the MHC Class I arm of the immune response. VLPs
released from transfected cells could further enhance
immunogenicity by entering another round of normal
target cells via fusion of the viral envelope glycoprotein
(Env) with the host cell’s plasma membrane (Hernandez et
al., 1996). This process may allow presentation of viral
antigens, in a manner analogous to that of natural HIV-1
infection. This theoretical advantage may be realized only
if the released VLPs are functional with regard to fusion
and entry into additional target cell populations. Further-
more, this advantage would not be available to VLP-
producing HIV-1 DNA vaccines that encode only Gag or
encode Gag, Env, and other viral proteins on separate
DNA constructs (Barouch et al., 2000, 2002; Kang et al.,
1999).
The generation of fusion-competent VLPs from cells
acquiring multigene HIV type 1 (HIV-1) DNA vaccines isFig. 1. Schematic representation of vaccine construct IC1. Subtypes A and G regi
are included for genomic reference. Brackets indicate genomic regions cloned intcomplicated by the dysregulation of viral gene product
expression. In natural virus maturation, protease activity
increases dramatically following budding from the host
cell, resulting in the complete processing of the three HIV-
1 precursor proteins and thus maturing the virus to its
infectious form (Gottlinger et al., 1989; Peng et al., 1989).
Intracellular activation of protease, instead of extracellular
activation, may cause aggregation of viral proteins, limit-
ing VLP production, and results in the appearance of
immature and aberrant virus-like structures (Karacostas et
al., 1993). Furthermore, a large accumulation and retention
of HIV proteins within expressing cells is not a normal
aspect of viral replication and may not promote processing
of peptides derived from endogenous antigens within the
cytoplasm of the cell and that are most effectively elim-
inated by cytotoxic T lymphocytes.
We undertook this study to improve the potential
immunogenicity of our DNA vaccine construct. Our
results show that by altering or mutating the HIV
protease, we can shift the qualitative production of HIVons are identified. Stippled region of genome is unclassified subtype. LTRs
o vector pGA1.
Table 1
Mutations introduced in vaccine constructsa
Vaccine construct Safety mutationsb,c Protease mutationsd
IC1 None None
IC2 gag NC, pol RT None
IC25 gag NC, pol RT D25N
IC48 gag NC, pol RT G48V
IC90 gag NC, pol RT M90L
a For details, see Materials and methods.
b Gag P7 nucleocapsid (zinc finger 1 and 2) positions 390, 393, 411, and
414 (all C to S).
c Pol RT position D185N, W266T, and E478Q.
d Position of amino acid change in pol protease.
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oped VLPs as well as protein aggregates could provide
distinct advantages to only one HIV product, providingFig. 2. HIV-1 Gag and Env expression by IC1 and IC2 vaccine constructs. (A)the best level of protection by controlling HIV-1 replica-
tion and perhaps infection.Results
Expression of vaccine construct HIV proteins
A representative CCR5 using HIV-1 CRF02_AG isolate
from an incident infection in Abidjan was selected to
begin construction of a multigene DNA vaccine. Using
viral RNA derived from the peripheral blood of this
individual, the 5VGag-Pol (gag, protease, and RT) and 3V
Env (vpu, tat, rev, and env) fragments were recombined in
the pGA1 expression vector to establish the model con-
struct, labeled Ivory Coast (IC) IC1 (Fig. 1). Two HIV
genes within IC1 were then mutated by site-directedGag and (B) Env expression were measured by antigen-specific ELISA.
Fig. 3. Transmission electron microscopy of HIV-1-like particles in 293T
cells transfected with vaccine construct IC2.
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use in humans. Mutations in gag NC to disable the zinc
fingers and pol RT to inactivate viral RT activity were
completed to establish the parental vaccine candidate IC2
(Table 1). The effects of these safety mutations were
verified by appropriate RNA packaging and RT activity
assays (data not shown). Despite the disablement of the
Gag zinc fingers, processing of the Gag precursor was
observed in our vaccine constructs. We did, however,
observe some accumulation of Pr41, suggesting that the
processing was slightly delayed, similar to findings by
others (Mizuno et al, 1996).
HIV-1 protein (Gag and Env) expression for these
constructs was then compared by examining cell lysates
and culture supernatants by ELISA following transient
transfection of 293T cells (Figs. 2A and B). HIV-1 protein
expression by IC1 was greater than 1.0 Ag/ml of Gag p24
and 85 ng/ml of Env in the lysate and supernatant,
respectively. No reduction of Gag and Env expression
was observed for IC2, because of the introduction of
safety mutations, as compared with IC1. Gag production
continued to increase for both constructs through 72 h;
however, after 24 h, lysis of transfected cells was observed
to release proteins directly into the supernatant.
Because these vaccine candidates are multigene con-
structs, VLP production from transfected cells was ex-
pected. To determine whether VLP formation occurred,
IC2-transfected 293T cells were examined by transmission
electron microscopy (Fig. 3). Surprisingly, only a limited
number of VLPs (approximately 100 nm in size) were
observed along with an abundance of protein aggregates.
The lack of VLPs and the appearance of protein aggregates
were not a result of the safety mutations, as similar findings
were observed for IC1 (data not shown). The protein
aggregates were presumably HIV-related proteins, as they
were not observed in mock-transfected 293T cells (data not
shown).
Demonstrable HIV protein expression from genetic
alteration of protease activity
Because VLP assembly and release from cells depend on
proper intracellular protease regulation to preserve the Gag
polyprotein (Gottlinger et al., 1989; Karacostas et al., 1993;
Peng et al., 1989) and may be observed upon transfection of
Gag-only expression systems (Huang et al., 2001; Kang et al.,
1999; Schneider et al., 1997), anHIV-1 protease inhibitor was
added to the transient transfections in an attempt to improve
the efficiency of VLP assembly. We treated 293T cells
following IC2 transfection with saquinavir (Jacobsen et al.,
1995), and as expected, the formation of Gag p24 was
significantly reduced in the presence of this compound
(Fig. 4A). Saquinavir-treated cultures (100 nM) contained
almost exclusively p55 and p41 (>99% of the immunoreac-
tive protein) and only trace levels of p24 (<1% of the
immunoreactive protein).Examination of saquinavir-treated, IC2-transfected
293T cells by transmission electron microscopy demon-
strated the presence of budding structures and production
of morphologically immature (electron-dense shells repre-
senting the virus core and with electron-lucent centers)
and uniformly sized VLPs (Fig. 4B). The number of these
particles and the lack of protein aggregates were in
marked contrast to IC2-transfected 293T cells not treated
with protease inhibitor (Fig. 3).
Restored particle formation from genetic alteration of
protease activity
The results obtained with the protease inhibitor sug-
gested that genetic modification of protease activity might
enhance production of VLPs from the vaccine constructs.
Previous studies demonstrated that alteration of the 25th
residue of protease, from Asp (D) to Asn (N), resulted in
complete loss of protease activity (Gottlinger et al., 1989;
Kohl et al., 1988; Loeb et al., 1989). Furthermore,
Jacobsen et al. (1995) demonstrated that mutagenesis of
protease at positions 48 (G48V) and 90 (M90L) led to
less efficient enzymatic activity and delayed processing of
the gag and gag-pol polyproteins. Accordingly, we creat-
ed three protease mutant constructs (IC25, IC48, and
Fig. 4. Processing of Gag polyprotein in the presence or absence of saquinavir. Cells were treated with two different concentrations of saquinavir as indicated.
(A) IC2-transfected 293T cell supernatants 24 h posttransfection were harvested, separated by SDS PAGE, transferred to nitrocellulose, and analyzed by
immunoblotting with rabbit polyclonal anti-p24. The positions of Gag proteins are indicated on the right. (B) Transmission electron microscopy of HIV-1-like
particles in 293T cells transfected with vaccine construct IC2 in the presence of 100 nM saquinavir.
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dent positions–25, 48, and 90—by site-directed mutagen-
esis (Table 1).
Gag expression was detected by antigen-capture ELISA
following 293T cell transfection, and two protease mutant
constructs (IC48 and IC90) appeared to express as well as IC2
(Fig. 5A). Gag expression of IC25 appeared sharply dimin-
ished as compared with IC2 and the other protease mutant
constructs. However, as previously reported (Schneider et al.,
1997), the detection efficiency of Gag p55 was substantially
less than that of Gag p24. Quantification of total Gag protein
of the IC25 supernatant by Western blot analysis (Fig. 5B),
using an anti-Gag antibody with reactivity against multiple
cleavage products, demonstrated that IC25 expressed Gag
protein to a level equal to if not greater than the level of the
other constructs (Fig. 5B). For IC25, the Gag protein was
primarily p55 and other Gag polyproteins (87% of the
immunoreactive protein) as expected in the absence of
protease enzymatic activity. For IC2, IC48, and IC90, the
majority of Gag immunoreactive protein was Gag p24 (87%,
56%, and 68%, respectively).Production of Env protein by the various multigene
vaccine constructs was also detected by ELISA (Fig. 5C).
Comparable levels of total Env expression were detected for
IC2, IC25, and IC48, but levels were diminished with IC90.
A greater percentage of total Env protein was detected in the
supernatant of all three protease mutant constructs as
compared with IC2, raising the possibility of more efficient
release by VLP assembly.
Detection of processed HIV proteins from
sucrose-gradient-banded VLPs
To more accurately assess the assembly of VLPs,
transfection culture supernatants were banded through a
sucrose gradient and subsequent fractions were examined
for the presence of Gag p24. Peak Gag p24 fractions
were then analyzed by immunoblotting using rabbit
polyclonal anti-p24 antibody (Fig. 6A). Only two Gag
polyproteins, p55 and p41, were detected for IC25.
However, three forms of Gag (p55, p41, and p24) were
observed for IC48 and IC90, indicating cleavage of the
Fig. 5. HIV-1 Gag and Env expression in transfected 293T cells with
various DNA vaccine constructs. (A) Gag expression in culture super-
natants and cell lysates 24 h posttransfection were measured by antigen-
specific ELISA. (B) Transfected cell culture supernatant Gag proteins were
analyzed by immunoblotting using a rabbit polyclonal anti-p24 antibody as
measured by a phosphorimager. (C) Env expression in culture supernatants
and cell lysates 24 h posttransfection were measured by antigen-specific
ELISA.
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which included the mature core (p24) protein. The
sucrose-gradient-banded VLP preparations from IC25
and IC48 also incorporated significant levels of surface
HIV Env, but levels were decreased with IC90 (confirm-
ing the outcome of Env ELISA (Fig. 5C)). As anticipated
for a multigene construct, upon immunoblotting of su-
crose-gradient-banded VLP, only the cleaved gp120 Env
glycoprotein was detected while no gp160 precursor
molecules were observed (Fig. 6B).Confirmation of mature VLP assembly from partial
inactivation of protease
To further confirm that genetic inactivation (i.e. IC25) or
partial inhibition (i.e. IC48) of protease activity permitted
VLP assembly and possible particle maturation, cells trans-
fected with protease-mutant vaccine constructs were exam-
ined by electron microscopy (Fig. 7). For IC25, immature
VLPs were seen (Fig. 7A). These particles were uniformly
sized, abundant in number, and similar in appearance
(electron-dense shells and lucent centers) to those formed
by expression in the presence of saquinavir (Fig. 4B).
Budding structures and numerous VLPs were also observed
for IC48 (Fig. 7B). But, two distinctive particle morpholo-
gies were observed: VLPs with a spherical protein shell
(immature) and other particles with electron-dense centers
(mature). Furthermore, the VLP with electron-dense centers
had a lean spherical protein shell, suggesting cleavage of
Gag p55 and condensing of the viral core, comparable to
mature HIV particles. IC48-transfected cells were also
observed to contain aggregates of HIV proteins (Fig. 7C),
and overall, fewer VLPs were observed than with IC25-
transfected cells. Although, total Gag production among
these constructs was similar, Gag production by IC25
appeared to be entirely VLP based, while Gag production
by IC48 was divided between multiple antigenic forms,
including protein aggregates, immature VLPs, and mature
VLPs.
Fusion and entry of mature HIV-like particles into target
cells
To determine if VLP-incorporated Env was fusion
competent and coreceptor specific and if maturation of
the core would influence entry, we measured the entry of
noninfectious VLPs from IC25 and IC48 into target cells.
Using GHOST-4 cells stably expressing either CXCR4 or
CCR5, the products from transfection with either IC25 or
IC48 (engineered into the IC1 backbone to increase the
level of RNA packaging) were evaluated for entry by
detection of post-fusion intracellular HIV RNA (Fig. 8).
Intracellular viral RNA was not detected after GHOST-4
were exposed to supernatants from mock transfections and
no amplified products were observed in any samples by
nested DNA PCR without first generating cDNA by a RT
step (data not shown). A background level of VLP entry,
presumably by endocytosis and the ability of some CCR5-
using virus to enter CXCR4 cells, was observed in
CXCR4-expressing cells and was similar in magnitude
for both IC25 and IC48 products (Fig. 8). Similar levels
of background were observed for experiments using
parental GHOST-4 cells (data not shown). Entry of the
non-mature VLPs produced by IC25 into CCR5-express-
ing cells did not score above the level observed as
background. However, entry of products from IC48 trans-
fection, including mature VLPs, into CCR5 target cells
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Fig. 6. Immunoblot analysis of sucrose-gradient purified HIV-1-like
particles using (A) rabbit polyclonal anti-p24 and (B) goat polyclonal
anti-gp160. The positions of HIV precursors and products are indicated on
the right. Fraction 9 from each gradient was separated by SDS-PAGE,
transferred to nitrocellulose, and analyzed by immunoblotting.
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results confirm that the unique products of IC48 vaccine
constructs enter cells in a manner analogous to wild-type
HIV-1 fusion and may provide additional immunologic
advantages.Fig. 7. Transmission electron microscopy of HIV-1-like particles in 293T
cells transfected with vaccine constructs expressing HIV genes. (A) IC25,
(B) IC48, and (C) IC48. Budding, extracellular immature and mature HIV-
like particles are identified.Discussion
We describe the generation and optimization of HIV-1
DNA vaccine constructs based on the recombinant
CRF02_AG subtype. The choice of isolate as the basis
of these vaccine constructs was the result of extensive
molecular epidemiological surveys recently conducted in
Coˆte d’Ivorie (Ellenberger et al., 1999, 2002; Nkenga-
song et al., 2000). Among the potential vaccine candi-
dates, a particular isolate from an incident HIV infection,
whose Env preferentially utilized CCR5 and whose
sequence closely aligned with the consensus sequence
for this survey, was chosen. These HIV-1 vaccine con-
structs should be considered applicable to potential trials
throughout broad areas of Western and West-Central
Africa where the CRF02_AG subtype predominates
(Andersson et al., 1999; Carr et al., 1998; Laurent et
al., 2002; McCutchan et al., 1999; Montavon et al., 2000;
Nkengasong et al., 2000; Peeters et al., 2000; Toure-Kane
et al., 2000). Furthermore, because these constructs are
subtype A in gag and a substantial portion of env (Fig.
1), they could serve as candidate vaccines in larger
Fig. 8. Detection of viral RNAwithin GHOST-4-CXCR4 and -CCR5 target cells by RT-PCR. Neat culture supernatant from 293T cells, 24 h after transfection
with either IC25 or IC48 was added to GHOST-4 cells for 1 h at 37jC. VLPs bound to the cell surface were removed by trypsin treatment. Following RNA
extraction, viral RNA was detected by PCR, using HIV specific primers.
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recombinant forms of subtype A exist (Ellenberger et
al., 2002). These vaccine candidates might also be
considered for use in geographic regions where HIV-1
subtype G circulates since subtype G comprises 26% of
the vaccine, including the immunodominant region of
Env gp41 and other genomic regions.
We sought to optimize expression from the DNA
vaccine constructs, not only in terms of high-level
production of HIV-1 proteins, but also with regard to
assembly of VLPs. In addition to the provision of
multiple viral gene products and potential for broad
immune response, in vivo production of VLPs is another
advantage of a multigene DNA vaccine approach when
viral products are all expressed on a single construct. In
this manner, the products from these vaccine constructs
may mimic the highly effective immunization achieved
with live-attenuated and live-defective virus vaccines,
without the potential risk of causing infection and
disease (Daniel et al., 1992; O’Neill et al., 2002) or
integration. Furthermore, when the use of these DNA-
based vaccines is combined with a boost immunization,
such as a modified vaccinia (MVA) construct encoding
the same antigens, generation of a potent and broad
cellular immune response characteristic of protective
DNA-MVA vaccine regimens (Amara et al., 2001) would
be anticipated.
It is well established that VLPs can be generated by
expression of only HIV-1 gag (Gheysen et al., 1989) and
that single gene ‘‘gag-only’’ vaccine constructs generate
VLPs following transfection of human cells (Huang et
al., 2001). Although the plasmid constructs used in our
study contain seven HIV-1 genes (including the pol
protease) from an HIV-1 CRF02_AG strain, we stillfound it surprising that the parental IC2 vaccine construct
failed to assemble VLPs to any appreciable extent.
Because the viral protease is lacking in VLP-expressing
gag-only constructs, we rationalized that aberrant intra-
cellular activation of protease or premature cleavage of
the gag polyprotein was limiting VLP assembly and
budding from IC2 transfected cells. When IC2 protease
activity was eliminated chemically or by direct mutagen-
esis of the catalytic site (IC25 construct), abundant
immature VLPs with electron-dense shells and lucent
centers were observed (Figs. 4B and 7A), much like
those seen with gag-only constructs. Importantly, the
introduction of protease mutations did not reduce the
overall level of viral protein expression from the vaccine
constructs. Therefore, strict regulation of protease func-
tion is critical for the optimal assembly of VLPs from
multigene HIV-1 DNA vaccine constructs, especially
when high-level expression is driven by a foreign pro-
moter (CMV promoter in IC2-derived constructs). In
contrast, a multigene SIV DNA vaccine construct, mutat-
ed in only the gag nucleocapsid, was capable of produc-
ing virus particles (Gorelick et al., 2000), possibly
because of more stringent control over viral protein
expression via its autologous LTR promoter.
We sought to further optimize the products from these
HIV-1 multigene DNA vaccine constructs by exploring
alterations that would permit not only VLP assembly and
budding but also core maturation and condensation. By
developing the multigene constructs IC48 and IC90,
which incorporate protease mutations found in some
HIV-infected persons with resistance to protease inhibi-
tors, expression in vitro resulted in the production of
mature VLPs as determined by core condensation. Prote-
ase mutations at either amino acid positions 48 or 90
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(Jacobsen et al., 1995), unlike the D25N mutation (Kohl
et al., 1988), and permit production of infectious virus
when present within an otherwise wild-type provirus.
Therefore, with the IC48 and IC90 vaccine constructs,
aberrant intracellular protease activity was presumably
diminished and VLP assembly directed by the intact
Gag polyprotein precursor could occur. As is the case
with wild-type HIV-1, protease functions after the bud-
ding of immature VLPs generated by IC48 or IC90 to
allow for core condensation and maturation.
It was generally accepted that the main route of entry
for HIV-1 is viral fusion with the plasma membrane
(Hernandez et al., 1996). Maturation of the viral core
appears to be an important determinant as observed for
IC48, where significantly more VLP entered coreceptor-
specific target cells than observed for IC25. Recently, it
was suggested that the host cell via endocytosis takes up
most HIV-1 particles that bind to the cell surface (Fred-
ericksen et al., 2002; Marechal et al., 1998; Schaeffer et
al., 2001). Our results indicate that immature VLP are
binding to the cell surface and entering target cells by
way of endocytosis regardless of the coreceptor molecule.
Furthermore, IC48 VLPs appear to enter both target cells,
but a greater proportion of VLP entered CCR5 cells,
suggesting VLPs with matured cores may be an improve-
ment over the immature VLP, using both the endocytic
and cytosolic pathways for processing.
After budding from the muscle or other cell type in
vivo that first acquires the DNA vaccine, mature VLPs
potentially can enter additional distant dendritic cells. This
entry mechanism would be analogous to a natural HIV
infection, especially if the VLPs contain matured cores,
using the cytosolic pathway for antigen processing and
promoting a greater likelihood for MHC Class I and II
presentation. Furthermore, these multigene DNA vaccine
constructs contain a CCR5-utilizing envelope, and mature
gp120 Env was detected in banded VLP preparations (Fig.
6). The HIV-1 Env protein is necessary for productive
entry into target cells, and inclusion of env in similar DNA
vaccine constructs was critical for the control of a SHIV
challenge (Amara et al., 2002). Assembly of native trimer-
ic forms of Env on the surface of mature VLPs and
subsequent postfusion processing and presentation of these
antigens may lead to still-unappreciated aspects of humoral
immunity to challenge. Furthermore, fusion-mediated entry
of mature VLPs analogous to a wild-type HIV-1 infection
may generate, after subsequent antigen processing, presen-
tation of more conserved or masked epitopes and provide
better cross-subtype recognition. Preliminary in vitro
experiments suggest that IC48 supernatant is capable of
being recognized by persons’ T cells infected with HIV of
different subtypes.
In addition to producing mature VLPs, the DNA
vaccine candidates IC48 and IC90 also generate HIV
protein aggregates and immature VLPs. Soluble andsecreted HIV-1 protein aggregates encoded by the
injected DNA may be processed and presented in the
context of MHC Class II molecules, stimulating B-cell
immunity by generating antibodies and B-cell memory
against the proteins. Immature VLPs may enter cells via
phagocytosis or endocytosis, as found with other viral
particles (Marechal et al., 1998; Schaeffer et al., 2001),
and may also be a source of immunogens via the MHC
class II pathway. Furthermore, on the surface of cells
acquiring the DNA construct (muscle or dendritic anti-
gen-presenting cells), peptides from the proteins encoded
by vaccine are also presented by the MHC Class I
pathway, after the proteins are processed as endogenous
antigens. Resulting immunogens are expressed in a native
conformation; thus, there may be an effective stimulation
of CD8+ CTL and MHC Class I-restricted pathway
presentation of the antigens. Cellular immunity has an
important role in the control of immunodeficiency virus
infections (Goulder et al., 1999) and protection against
challenge with HIV (Amara et al., 2001; Barouch et al.,
2000; McMichael and Phillips, 1997; Oldstone 1997;
Rowland-Jones et al., 1997). Evidence further suggests
that cytotoxic T-lymphocyte cross-reactivity will be an
important component of a single efficacious HIV vaccine
(Buseyne et al., 1998; Cao et al., 1997; Ferrari et al.,
1997; McAdam et al., 1998; Rowland-Jones et al., 1999).
In a macaque model of retroviral challenge, control of
viremia that correlated with protection from disease was
observed with a SHIV DNA vaccine, similar in compo-
sition to those described here, and MVA boost (Amara et
al., 2001). We have determined that the SHIV DNA
vaccine construct forms aggregates in vitro (data not
shown), as expected based on wild-type protease (similar
to IC2). Furthermore, in a recent nonhuman primate
immunogenicity trial evaluating HIV-1 subtype B vac-
cines, DNA constructs that produce only immature VLPs
(with protease mutation at amino acid 25) showed en-
hanced ability to stimulate an immune response, especially
humoral immunity, when compared with aggregate-form-
ing DNA constructs (H. Robinson, personal communica-
tion). Therefore, the development and characterization of
HIV-1 DNA vaccines that generate a balance of these
different antigenic forms may provide distinct immuno-
logic advantages and may further advance vaccine devel-
opment. In addition, production of mature virus-like
particles, which may behave similarly to attenuated live-
virus vaccines but without risk of integration or causing
AIDS, is clearly an obtainable goal for multigene HIV-1
DNA vaccine approaches. It remains to be determined
from the outcome of ongoing nonhuman primate trials,
testing IC25 and IC48 immunogenicity, whether these
vaccine constructs, especially when coupled with an
MVA-based boost immunization, will provide the unique
immunologic advantages for specific and cross-subtype
cellular and humoral responses as suggested by their
unique in vitro characteristics.
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DNA immunogens
HIV-1 was obtained from a female sex worker in Abidjan,
Coˆte d’Ivoire. An incident recombinant HIV-1 subtype A/G
(CRF02_AG) strain was chosen (Ellenberger et al., 2002).
HIV-1-specific reverse transcriptase (RT)-PCR was done on
total RNA recovered from a plasma sample. Gag (amino
acids 1–496) and Pol (amino acids 1–728) (GenBank
accession no., AY227361); Vpu (amino acids 1–82), Tat
(amino acids 1–102), Rev (amino acids 1–84) and Env
(amino acids 1–854) (GenBank accession no., AY227362)
from IC0928 were reverse transcribed, and fragments pro-
duced by DNA PCR were cloned into the pGA1 expression
vector (GenBank accession no., AF425297). Sense primer 1
(5V-AAGATCTATCGATGCAAGGACTCGGCTTGC-3V)
and antisense primer 2 (5V-TTCCAATTGCTGTGA-
GAATTCTCATGCTCTTCTTGGG-3V) were used to ampli-
fy the 5VPCR product. The 5VPCR product encompassed
the gag, protease, and RT genes and was cloned by intro-
ducing a stop codon and a unique EcoRI restriction site at 12
amino acid residues downstream of the RT and integrase
junction. Sense primer 3 (5V-AAGGGGTTAAAGCTATAA-
TAAGAA-TTCTGCA-3V) and antisense primer 4 (5V-
CCTTT-GCTGCCCTATCTGATTCTTCTAGG-3V) were
used to amplify the 3VPCR product.
The 3VPCR fragment encompassed the vpu, tat, rev, and
env sequences and the splice acceptor sites necessary for
proper processing and expression of their respective
mRNAs. The 3VPCR product was cloned using an EcoRI
restriction site (88 bp upstream of the Tat start site) and
introducing a stop codon and unique NheI and RsrII restric-
tion sites, truncating Env by seven amino acid residues.
The inactivating codon mutations were made using a
site-directed mutagenesis kit (Stratagene, La Jolla, CA)
following the manufacturer’s protocol. All mutations were
confirmed by sequencing. Primer pairs used for the muta-
genesis were:
Sense primer C390S 928 ZN1 (5V-GCCAGAGAATAA-
TAAAGaGcTTCAACaGcGGCAAAGAAGG-3V) and anti-
sense primer C393S 928 ZN2 (5V-CCTTCTTTGCCgCt-
GTTGAAgCtCTTTATTATTCTCTGGC-3V); sense primer
C411S 928 ZN3 (5V-CCTAGAAAGAGAGGCaGcTG-
GAAAaGcGGAAAGGAAGG-3V) and antisense primer
C414S 928 ZN4 (5V-CCTTCCTTTCCgCtTTTCCAgC-
tGCCTCTCTTTCTAGG-3V); sense primer D185N 928
RT1 (5V-CCAATATATGaAcGATTTATATGTAGGATCT-
GAC-3V) and antisense primer D185N 928 RT2 (5V-GTCA-
GATCCTACATATAAATCgTtCATATATTGG-3V); sense
primer W266T 928 RT3 (5V-GGGAAAACTAAATaccG-
CAAGTCAGATTTATGCAGG-3V) and antisense primer
W266T 928 RT4 (5V-CCTGCATAAATCTGACTTGCgg-
tATTTAGTTTTCCC-3V); and sense primer E478Q 928
RT5 (5V-CCCTAATTGAGACAACAAATCAAAAGACT-
cAgTTACATGC-3V) and antisense primer E478Q 928RT6 (5V-GCATGTAAcTgAGTCTTTTGATTTGTTGTCT-
CAATTAGGG-3V).
All protease mutations were made from a ClaI-to-XmnI
fragment (1995 bp) subclone (Table 1). The Asp-to-Asn
substitution at position 25 (IC25), the Gly-to-Val substitution
at position 48 (IC48), and the Met-to-Leu substitution at
position 90 (IC90) were created by PCR with primers con-
taining the mutations. The PCR-amplified mutated products
were cloned back into the IC1 backbone. The mutations were
made using a site-directed mutagenesis kit (Stratagene)
following the manufacturer’s protocol. All mutations were
confirmed by sequencing. Primer pairs used for the muta-
genesis were:
Sense primer D25N 928 Prt1 (5V-GCCAATAGAAGC-
CCTATTAaACACAGGAGC-3V) and antisense primer
D25N 928 Prt2 (5V-GCTCCTGTGTtTAATAGGGCTTC-
TATTGGC-3V); sense primer G48V 928 Prt3 (5V-CCAAA-
AATGATAGtGGGAATTGGAGG-3V) and antisense primer
G48V 928 Prt4 (5V-CCTCCAATTCCCaCTATCATTTT-
TGG-3V); and sense primer M90L 928 Prt5 (5V-GGAC-
GAAATATGaTGACTCAGATTGGT-3V) and antisense
primer M90L 928 Prt6 (5V-ACCAATCTGAGTCAtCA-
TATTTCGTCC-3V).
Cell lines
Human 293T cells, a human kidney-derived cell line,
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum.
GHOST-4 cells, expressing the human CD4 gene in com-
bination with either CXCR4 or CCR5 (Morner et al., 1999),
were obtained from the National Institute of Allergy and
Infectious Diseases AIDS Research and Reference Reagent
Program (Rockville, MD). GHOST-4 cell cultures were
maintained in DMEM supplemented with 10% fetal bovine
serum, 1 Ag/ml puromycin, 100 Ag/ml hygomycin B, and
500 Ag/ml G418.
Transient transfections
293T cells were added at 106 cells per well of Costar six-
well plates in 2 ml of DMEM growth medium and incubated
for 24 h at 37jC in a 5% CO2 humidified atmosphere. After
24 h, LipofectAmine2000 reagent (Invitrogen, Carlsbad, CA)
and plasmid DNAwere mixed according to the manufactur-
er’s protocol and added to each well. Supernatants were
harvested 24 or 48 h following the addition of transfection
reagents. For protease inhibitor experiments, saquinavir (15
or 100 nM) was added to transfection cultures immediately
following the addition of plasmid DNA.
Antigen-capture assay
Assay was performed using an HIV-1 antigen-capture
EIA kit (Coulter, Hialeah, FL) according to the manufactur-
er’s instructions.
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Pooled human immunoglobulin anti-HIV (catalog no.
3957) was obtained from the National Institute of Allergy
and Infectious Diseases AIDS Research and Reference
Reagent Program (Rockville, MD). Affinity-purified sheep
polyclonal anti-gp120 was purchased from International
Enzymes, Inc. Ninety-six-well plates were coated with 100
Al of 2 Ag/ml of anti-gp120 in carbonate buffer and incubated
at 4jC for 18 h. Samples were added to the wells following
three washes and blocking, and incubated for 1 h at room
temperature. Following three washes, 100 Al/well of 1:5000
dilution of HIV-Ig was added to each well and incubated for
1 h at room temperature. Following three washes, 100 Al/
well of 1:10,000 dilution of anti-human-HRP was added, and
incubated for 1 h at room temperature. Then, 100 Al of
substrate was added and incubated for 5 min. The reaction
was stopped by adding 25 Al of 2 M H2SO4. The plates were
read at 450 nm and data were analyzed using four-parameter
analysis for a standard curve.
Antibodies and Western blot analysis
Rabbit polyclonal anti-p24 (catalog no. 4250) and goat
polyclonal anti-gp160 (catalog no. 188) were obtained from
the National Institute of Allergy and Infectious Diseases
AIDS Research and Reference Reagent Program. Western
blot analysis was performed as previously described (Sam-
brook et al., 1989). HIV-1 protein bands were visualized
using the ECL Western blotting detection reagent (Amer-
sham Pharmacia Biotech, Piscataway, NJ) as described by
the manufacturer. Expression levels were determined using
a phosphorimager.
Purification of particles
Following 24 h of transient transfection of 293T cells,
culture supernatants were recovered, clarified by centrifu-
gation at 200  g  5 min, and 1 ml was layered on top
of 10–50% sucrose gradients. Gradients of 10 ml con-
sisting of 2 ml each of 50%, 40%, 30%, 20%, and 10%
sucrose solutions were added to ultraclear centrifuge tubes
from bottom to top. Gradients were centrifuged at 40,000
rpm for 16 h in SW41Ti rotor. Fractions of 1 ml were
recovered, top to bottom. Fraction aliquots were analyzed
by HIV-1 p24-antigen capture assay.
Electron microscopy
Transfected 293T cells were fixed in the multiwell plate
using 1 ml of 2.5% glutaraldehyde in 0.1M cacodylate buffer
for 2 h at 4jC. After three washes with the same buffer, 1.0%
osmium tetroxide in 0.1 M cacodylate buffer was added,
incubated for 1 h, dehydrated through an ethanol series, and
embedded with Eponate 12 resin. Following polymerization
of the resin, the cells were sectioned en face, stained with 4%uranyl acetate in water and lead citrate, and observed on a
Hitachi H-7500 transmission electron microscope.
Viral entry assay
GHOST-4 cells expressing either CXCR4 or CCR5
(Morner et al., 1999) were added at 0.6  106 cells per
well of Costar six-well plates in 2 ml of GHOST growth
medium and incubated for 24 h at 37jC in a 5% CO2
humidified atmosphere. The culture medium was then
replaced with 600 Al of neat culture supernatant from
293T cells, 24 h after transfection with either IC25 or
IC48 (engineered into the IC1 backbone to increase the
level of RNA packaging). After 1 h at 37jC, the cells were
washed three times with 1 ml of PBS and then trypsin-
treated [600 Al of 0.05% trypsin–EDTA (Invitrogen)] at
37jC for 25 min with intermittent careful mixing. After
600 Al of DMEM containing 10% FBS was added, the
entire contents of each well were transferred to a centri-
fuge tube, pelleted (200  g  5 min), and washed twice
with PBS. Cells were pelleted once more and RNA was
extracted using an RNeasy kit (Qiagen, Chatsworth, CA),
according to the manufacturer’s instructions. After extrac-
tion, RNA was reconstituted in DEPC-treated water and
DNAse I treated. Ten-fold dilutions of RNA were used for
HIV-specific RT PCR. Thermal cycling conditions for RT-
PCR were as follows: 42jC, 15 min for 1 cycle; 99jC, 5
min for 1 cycle; and 5jC, 5 min for 1 cycle. Of the 20
Al cDNA reaction, 2 Al was used for DNA PCR. Thermal
cycling conditions for PCR were: 95jC, 2 min for 1 cycle;
denaturation, 95jC, 30 s; annealing, 55jC, 30 s; and
extension 72jC, 1 min for 35 cycles; and 72jC, 7 min
for 1 cycle. The primers for Env gp41 immunodominant
region amplification were as follows: RT-PCR, 41R+tail30
(5V-GAACATCGATGACAAGCTTAGGTATCGATAAAC-
GACAAAGGTGAGTATCCCTGCCTAA-3V); primary
PCR sense primer 40F (5V-TCTTAGGAGCAGCAG-
GAAGCACTATGGG-3V) and antisense primer tail30 (5V-
GAACATCGATGACAAGCTTAGGTATCGATA-3V); and
nested PCR sense primer 46F (5V-ACAATTATTGTCTGG-
TATAGTGCAACAGCA-3V) and antisense primer 47R (5V-
TTAAACCTATCAAGCCTCCTACTATCATTA-3V). An
HIV-1 env fragment of 460 bp was detected by ethidium
bromide staining of agarose gel.Acknowledgments
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